Legal

Medical disclaimer

Educational content only

GLP-1 Nutrition publishes general educational information about nutrition during therapy with GLP-1 receptor agonist medications. Nothing on this site — in any article, app review, research summary, or page — constitutes medical advice, a medical diagnosis, a treatment recommendation, an individualized care plan, or any other form of professional medical consultation.

No substitute for your clinician

The information published here does not replace, supersede, or substitute for the guidance of your prescribing clinician, your dietitian, your pharmacist, or any other licensed healthcare professional involved in your care. Decisions about whether to start, continue, change the dose of, or discontinue a GLP-1 receptor agonist medication are clinical decisions that must be made between you and your prescribing clinician. Do not start, stop, or change any medication, supplement, or dietary regimen based on what you read on this site.

No physician-patient relationship

Reading this site does not create a physician-patient, dietitian-patient, or any other clinical relationship between you and any author, reviewer, or contributor to GLP-1 Nutrition. The clinicians named on this site are not available to answer individual clinical questions through this website.

Urgent symptoms

If you are experiencing severe abdominal pain, persistent or intractable vomiting, signs of dehydration (dizziness, dark urine, very low urine output), signs of pancreatitis, signs of gallbladder disease, signs of bowel obstruction, severe hypoglycemia, an allergic reaction, or any other concerning symptom while taking a GLP-1 medication, contact your prescribing clinician immediately or seek emergency care. Do not consult this website in place of urgent medical attention.

Compounded medications

Compounded semaglutide, compounded tirzepatide, and similar non-FDA-approved formulations are not equivalent to the FDA-approved branded medications. The published clinical-trial evidence on which our content is based comes from studies of the FDA-approved formulations. Decisions about whether to use a compounded GLP-1 medication are clinical decisions that should involve a thorough conversation with your prescribing clinician about the benefits, risks, regulatory status, and alternatives.

App reviews

The calorie-, macro-, and dose-tracking apps reviewed on this site are general-purpose consumer health apps. None of them are FDA-cleared as medical devices for use in GLP-1 receptor agonist therapy. App tracking does not replace clinician follow-up, laboratory monitoring, or any element of formal medical care.

Pharmaceutical names

References to medication brand names (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Rybelsus, Bydureon, Byetta) are for editorial identification only. GLP-1 Nutrition has no commercial relationship with the manufacturers of these medications.

Liability

To the maximum extent permitted by applicable law, GLP-1 Nutrition, its editors, authors, reviewers, and contributors disclaim all liability for any loss, injury, or damage arising from the use of the information published on this site.

Last updated: April 2026.